2023
DOI: 10.3389/fimmu.2023.1069968
|View full text |Cite
|
Sign up to set email alerts
|

Performance of an interferon-γ release assay-based test for cell-mediated immunity to SARS-CoV-2

Abstract: In search for immunological correlates of protection against acute coronavirus disease 2019 (COVID-19) there is a need for high through-put assays for cell-mediated immunity (CMI) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We established an interferon-γ release assay -based test for detection of CMI against SARS-CoV-2 spike (S) or nucleocapsid (NC) peptides. Blood samples obtained from 549 healthy or convalescent individuals were measured for interferon-γ (IFN-γ) production afte… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 44 publications
0
2
0
Order By: Relevance
“…The reason for this could be attributed to the fact that methodologies used for the assessment of the cellular response are not as readily accessible, are expensive, necessitate a meticulous pre-analytical procedure (i.e., use of fresh whole blood samples), and entail a prolonged sample processing. Additionally, the development of such assays requires higher efforts compared to serological testing (18,33,39).…”
Section: Discussionmentioning
confidence: 99%
“…The reason for this could be attributed to the fact that methodologies used for the assessment of the cellular response are not as readily accessible, are expensive, necessitate a meticulous pre-analytical procedure (i.e., use of fresh whole blood samples), and entail a prolonged sample processing. Additionally, the development of such assays requires higher efforts compared to serological testing (18,33,39).…”
Section: Discussionmentioning
confidence: 99%
“…While IGRAs are commonly used for assessing cellular immunity in mycobacterial infections ( 12 ), specific assays have emerged to evaluate T cell responses to SARS-CoV-2 by measuring IFN-γ production ( 13 ). The SARS-CoV-2 IGRA has been shown to accurately distinguish between convalescent and healthy uninfected individuals ( 14 16 ), identify subjects with symptomatic and asymptomatic infection after seroconversion ( 7 ), and estimate the immunity after vaccination in convalescent and uninfected persons ( 17 19 ). However, the performance of the SARS-CoV-2 IGRA in patients with acute infection needing hospital admission is unknown.…”
Section: Introductionmentioning
confidence: 99%